The latest commentary in Frontiers in Toxicology titled "Bridging gaps between scientific research and regulatory decision-making in Europe: Roles of academia, risk assessors, and policymakers" sheds critical light on a persistent challenge in the European Union: the disconnect between cutting-edge toxicology research and its application in policy and regulation. Published on April 13, 2026, this piece by researchers from Spain's Carlos III Health Institute and Atova Regulatory Consulting urges a collaborative overhaul to ensure scientific advancements directly inform safer chemical policies.
At its core, the paper identifies misalignments among three key stakeholders—academia generating novel data, risk assessment bodies evaluating hazards, and policymakers crafting laws. These gaps slow the translation of toxicology findings into actionable EU frameworks, stalling innovation while leaving potential risks unaddressed. With over 23,000 chemicals registered under REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) requiring extensive safety data, the stakes are high for human health and environmental protection.
Understanding REACH and the Toxicology Data Imperative
Enacted in 2007, REACH represents the EU's cornerstone for chemical safety, mandating companies to submit dossiers proving substances can be used safely. Toxicology data forms the backbone, covering endpoints like acute toxicity, repeated-dose effects, reproductive harm, and carcinogenicity. Traditional reliance on animal testing generates this evidence but faces ethical, scientific, and logistical hurdles—millions of vertebrates tested annually across Europe.
REACH explicitly promotes alternatives via the 3Rs principle (Replacement, Reduction, Refinement), yet uptake lags. New Approach Methodologies (NAMs)—in vitro cell-based assays, organ-on-chip systems, and in silico computational models—promise human-relevant predictions without animals. However, regulatory validation remains a bottleneck, as agencies like the European Chemicals Agency (ECHA) demand robust evidence of reliability and relevance.
Key Gaps: From Lab Bench to Legislation
The Frontiers commentary pinpoints several disconnects. First, academic research often prioritizes publication over regulatory utility, producing data misaligned with ECHA's needs—like lacking GLP (Good Laboratory Practice) compliance or standardized formats. Second, risk assessors at bodies such as EFSA (European Food Safety Authority) and national institutes struggle with data overload and integration, exacerbated by siloed expertise. Third, policymakers face pressure from industry timelines and public demands, sometimes sidelining emerging science.
In toxicology specifically, gaps manifest in REACH's information requirements. For instance, while in silico tools predict skin sensitization with 80-90% accuracy in some cases, they rarely waive in vivo tests without Integrated Approaches to Testing and Assessment (IATA). A 2025 ECHA report highlights that NAMs fill only 20% of data gaps for complex endpoints like chronic toxicity.
Stakeholder surveys reveal further friction: 60% of researchers report unfamiliarity with regulatory guidelines, while 45% of assessors cite insufficient training in NAMs interpretation.
Roles of Academia in Bridging the Divide
European universities, home to toxicology hubs like INSERM in France and ISCIII in Spain, lead data generation. Yet, the paper calls for academia to adopt "fit-for-purpose" designs—aligning studies with REACH Annexes from inception. Initiatives like the EU's Horizon Europe-funded PARC (Partnership for the Assessment of Risks from Chemicals) exemplify this, uniting 50+ institutions to validate NAMs for hazard assessment.
Institutions such as Wageningen University (Netherlands) pioneer organoid models for liver toxicity, while Germany's Fraunhofer Institute advances QSAR (Quantitative Structure-Activity Relationship) models. By embedding regulatory liaisons and GLP training in curricula, universities can produce directly usable data, fostering PhD programs in regulatory toxicology.
Photo by Christian Lue on Unsplash
Risk Assessors and Policymakers: The Gatekeepers
Risk assessment bodies like ECHA and EFSA translate data into opinions, but face capacity strains—ECHA processed 2,500 dossiers in 2025 alone. The commentary advocates pre-competitive data sharing platforms to harmonize inputs. Policymakers, via the European Commission, must update REACH (e.g., proposed 2025 revisions) to explicitly accept validated NAMs, as in the ongoing roadmap to phase out animal testing by 2035.
Industry, through groups like Cefic, pushes for IATA acceptance, citing cost savings: NAMs could slash REACH compliance expenses by €1-2 billion annually.
Case Studies: NAMs in Action Amid Challenges
The PARC initiative demonstrates progress: Work Package 5 develops NAMs for immunotoxicity and reproductive endpoints, integrating multi-omics data. Early pilots show 75% concordance with animal data for skin corrosion. Conversely, PrecisionTox project reveals hurdles—regulatory hesitation on probabilistic in silico predictions versus deterministic animal results.
In REACH evaluations, ECHA accepted read-across (grouping similar chemicals) for 40% of cases in 2025, up from 25% in 2020, but full NAM waivers remain rare (<5%). A notable success: Cosmetics Regulation bans animal testing since 2013, relying on NAMs via SCCS opinions.
Proposed Solutions: A Roadmap Forward
Drawing from the paper, solutions span levels: Regulatory—mandate NAM-friendly IATA in REACH updates; Funding—prioritize grants for regulatory-aligned projects (e.g., ERC's €1B toxicology call); Training—joint academia-regulator programs like ECHA's fellows scheme.
Open science platforms (e.g., ECHA's IUCLID) and AI-driven data curation could bridge harmonization gaps. The authors stress trust-building via workshops, echoing EPAA's NAM Designathon.
Implications for Higher Education and Research Careers
For Europe's 500+ toxicology programs (e.g., Imperial College London, KU Leuven), this signals a shift: curricula must integrate regulatory science. Demand surges for experts in computational toxicology—salaries average €70-100K, with 15% annual job growth per LinkedIn data.
Universities like Uppsala (Sweden) offer MSc in Regulatory Toxicology, preparing grads for ECHA/EFSA roles. Collaborative PhDs under PARC bridge academia-industry, enhancing employability.
Photo by Carl Gruner on Unsplash
Future Outlook: Toward Animal-Free Regulation
The EU's 2025 animal testing roadmap targets 30% NAM reduction by 2030, aligning with global trends (US FDA Modernization Act 2.0). Success hinges on stakeholder synergy, potentially saving 10M animals/year while accelerating safe chemical innovation.
Challenges persist—validating NAMs for chronic endpoints—but momentum builds via AI integration and pan-EU consortia.
Read the full Frontiers commentary and explore REACH details on ECHA.
This commentary arrives at a pivotal moment, as Europe grapples with chemical safety amid climate pressures and green transitions. By fostering collaboration, the tox research-policy bridge can safeguard public health while propelling EU leadership in ethical science.
